The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: A real-world analysis.
 
Preeti Bajaj
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines; Roche
Travel, Accommodations, Expenses - Revolution Medicines
 
Pranoti Pradhan
No Relationships to Disclose
 
Debbie (Yuexi) Wang
Employment - ConcertAI
Research Funding - Abbvie (Inst); Amgen (Inst); BeiGene (Inst); Kyowa Kirin International (Inst); Merck (Inst); Taiho Oncology (Inst); Teva (Inst)
 
Aliza Karpes-Matusevich
Research Funding - Evolent (Inst); Revolution Medicines (Inst)
 
Ziyu Lan
Employment - ConcertAI
Research Funding - Taiho Oncology (Inst)
 
Brandon Kent
Employment - Daiichi Sankyo/Astra Zeneca; Revolution Medicines
Stock and Other Ownership Interests - Daiichi Sankyo/Astra Zeneca; Revolution Medicines
 
W. Clay Gustafson
Employment - Natera (I); Revolution Medicines
Stock and Other Ownership Interests - Natera (I); Revolution Medicines
Patents, Royalties, Other Intellectual Property - Development of a novel class of molecules with unique mechanism of action developed to inhibit MYC proteins across multiple diseases. Our prototype molecule, CD532 has unique properties in neuroblastoma, breast cancer, colon cancer, and non-hodgkins leuke
Travel, Accommodations, Expenses - Natera (I); Revolution Medicines
 
John Graham
Employment - GlaxoSmithKline; Revolution Medicines
Stock and Other Ownership Interests - GlaxoSmithKline; Revolution Medicines